| Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ... Cancer discovery 6 (10), 1118-1133, 2016 | 1101 | 2016 |
| The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer L Friboulet, N Li, R Katayama, CC Lee, JF Gainor, AS Crystal, ... Cancer discovery 4 (6), 662-673, 2014 | 907 | 2014 |
| Patient-derived models of acquired resistance can identify effective drug combinations for cancer AS Crystal, AT Shaw, LV Sequist, L Friboulet, MJ Niederst, EL Lockerman, ... Science 346 (6216), 1480-1486, 2014 | 787 | 2014 |
| Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F AT Shaw, L Friboulet, I Leshchiner, JF Gainor, S Bergqvist, A Brooun, ... New England Journal of Medicine 374 (1), 54-61, 2016 | 525 | 2016 |
| PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models HY Zou, L Friboulet, DP Kodack, LD Engstrom, Q Li, M West, RW Tang, ... Cancer cell 28 (1), 70-81, 2015 | 464 | 2015 |
| Acquired resistance to crizotinib from a mutation in CD74–ROS1 MM Awad, R Katayama, M McTigue, W Liu, YL Deng, A Brooun, ... New England Journal of Medicine 368 (25), 2395-2401, 2013 | 453 | 2013 |
| ERCC1 isoform expression and DNA repair in non–small-cell lung cancer L Friboulet, KA Olaussen, JP Pignon, FA Shepherd, MS Tsao, S Graziano, ... New England Journal of Medicine 368 (12), 1101-1110, 2013 | 428 | 2013 |
| Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib R Katayama, L Friboulet, S Koike, EL Lockerman, TM Khan, JF Gainor, ... Clinical cancer research 20 (22), 5686-5696, 2014 | 328 | 2014 |
| Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? G Recondo, F Facchinetti, KA Olaussen, B Besse, L Friboulet Nature reviews Clinical oncology 15 (11), 694-708, 2018 | 303 | 2018 |
| Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer S Yoda, JJ Lin, MS Lawrence, BJ Burke, L Friboulet, A Langenbucher, ... Cancer discovery 8 (6), 714-729, 2018 | 269 | 2018 |
| Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer JF Gainor, D Tseng, S Yoda, I Dagogo-Jack, L Friboulet, JJ Lin, ... JCO precision oncology 1, 1-13, 2017 | 265 | 2017 |
| Cabozantinib overcomes crizotinib resistance in ROS1 fusion–positive cancer R Katayama, Y Kobayashi, L Friboulet, EL Lockerman, S Koike, AT Shaw, ... Clinical cancer research 21 (1), 166-174, 2015 | 217 | 2015 |
| Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer B Gong, K Kiyotani, S Sakata, S Nagano, S Kumehara, S Baba, B Besse, ... Journal of Experimental Medicine 216 (4), 982-1000, 2019 | 210 | 2019 |
| Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib JF Gainor, DSW Tan, T De Pas, BJ Solomon, A Ahmad, C Lazzari, ... Clinical cancer research 21 (12), 2745-2752, 2015 | 202 | 2015 |
| Primary patient-derived cancer cells and their potential for personalized cancer patient care DP Kodack, AF Farago, A Dastur, MA Held, L Dardaei, L Friboulet, ... Cell reports 21 (11), 3298-3309, 2017 | 198 | 2017 |
| SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors L Dardaei, HQ Wang, M Singh, P Fordjour, KX Shaw, S Yoda, G Kerr, ... Nature medicine 24 (4), 512-517, 2018 | 185 | 2018 |
| Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib IM Silverman, A Hollebecque, L Friboulet, S Owens, RC Newton, H Zhen, ... Cancer discovery 11 (2), 326-339, 2021 | 180 | 2021 |
| BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall A Leonetti, F Facchinetti, G Rossi, R Minari, A Conti, L Friboulet, M Tiseo, ... Cancer treatment reviews 66, 82-94, 2018 | 159 | 2018 |
| P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer R Katayama, T Sakashita, N Yanagitani, H Ninomiya, A Horiike, ... EBioMedicine 3, 54-66, 2016 | 158 | 2016 |
| Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers F Facchinetti, Y Loriot, MS Kuo, L Mahjoubi, L Lacroix, D Planchard, ... Clinical Cancer Research 22 (24), 5983-5991, 2016 | 144 | 2016 |
Jean-Charles SoriaAmgen R&DAdresse e-mail validée de amgen.com
